Cognitive-behavioral therapy in high-altitude respiratory care: Critical considerations for physiological interpretation

Abstract

High-altitude respiratory diseases, characterized by hypoxia-induced complications such as pulmonary edema and chronic bronchitis, present critical challenges to both physical and mental health in vulnerable populations. The recent study by Meng et al demonstrates that integrating cognitive-behavioral therapy (CBT) with standard care significantly improves anxiety levels and sleep quality in affected patients. These key findings hold direct implications for advancing respiratory management in hypoxic environments. Meng et al’s observation of reduced serum hypoxia biomarkers (hypoxia-inducible factor-1α and erythropoietin) further suggests potential enhancements in physiological adaptation. However, the interpretation of these biomarker changes as evidence of improved hypoxia tolerance requires cautious examination. The study’s reliance on indirect indicators fails to establish whether CBT’s benefits stem primarily from psychological modulation or genuine cellular adaptation. Furthermore, the 5-day intervention window coincides with the half-life of erythropoietin, raising questions about the durability of these effects in the context of hypoxic acclimatization, which typically requires weeks to months. To resolve these ambiguities, future studies should prioritize longitudinal designs tracking both respiratory function and molecular biomarkers over clinically relevant timeframes. Integrating CBT with objective pulmonary assessments would clarify its role in optimizing oxygen utilization pathways. Such advances could refine targeted interventions for high-altitude respiratory rehabilitation, ultimately strengthening evidence-based care for this unique patient population.

Keywords: Cognitive-behavioral therapy; High-altitude respiratory diseases; Hypoxia biomarkers; Physiological adaptation; Rehabilitation

Core Tip: Cognitive-behavioral therapy significantly alleviates anxiety and improves sleep quality in high-altitude respiratory patients. However, rapid reductions in hypoxia biomarkers (hypoxia-inducible factor-1α and erythropoietin) after 5-day interventions more likely reflect transient stress modulation than durable physiological adaptation, given their discordance with natural acclimatization timelines. Future studies should prioritize longitudinal biomarker tracking, objective physiological measures (e.g., tissue oxygenation), and medication-stratified analyses to definitively establish the role of cognitive-behavioral therapy in hypoxia tolerance—a distinction vital for optimizing high-altitude rehabilitation.